A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel

Phase 1 Terminated 10 enrolled Teva Branded Pharmaceutical Products R&D, Inc. Covance · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the chemical breakdown and excretion of talampanel and its break down products in plasma, feces, and urine of healthy human volunteers.

Timeline

Start: 2009-05
Primary completion: 2009-09
Completion: 2009-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Talampanel	Small molecule	50 mg	Oral

Indications

No indication recorded.